Intuitive Surgical’s (ISRG) stock price seemingly accounts for the expected launch of its next generation robot, but questions remain whether the new product would help the company achieve its growth metrics, UBS said in a note emailed Tuesday.
The company is expected to reveal details about its latest robot at the upcoming Society of American Gastrointestinal and Endoscopic Surgeon, or SAGES, meeting in April.
The key to Intuitive Surgical’s shares over the next 12 months will be determined by whether the product can accelerate the company’s procedure volume growth in 2025 and beyond and meaningfully increase the total addressable market, the firm noted.
UBS maintained its neutral rating on the company’s stock with a price target of $385.